Browsing by Author Dummer, R

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
Issue DateTitleAuthor(s)Citation
2012Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF InhibitionLong, Georgina; Busam, Klaus; Carvajal, Richard; Dummer, R; Egberts, Friederike; Goldinger, Simone; Hauschild, A; Hillen, Uwe; Kashani-Sabet, Mohammed; Lacouture, Mario; Livingstone, Elisabeth; McArthur, Grant A.; Schadendorf, Dirk; Scherag, Andre; Sucker, Antje; Zimmer, Lisa; Central Clinical School: The Sydney Cancer CentreAtypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition, Journal of Clinical Oncology, vol.30, 19, 2012,pp 2375-2383
2017Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialLong, Georgina; Arance, A; Ascierto, Paolo A; Del Vecchio, M; Di Giacomo, A; Dummer, R; Dutriaux, Caroline; et al, Various; Gutzmer, R.; Rutkowski, Piotr; Schadendorf, D; Northern Clinical School: MedicineBinimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial, The Lancet Oncology, vol.18, 4, 2017,pp 435-445
2017Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialTrotman, Judith; Dummer, R; et al, Various; Horwitz, Steven; Kim, Youn H; Prince, H. Miles; Quaglino, Pietro; Sanches, Jose; Scarisbrick, J; Wolter, Pascal; Zinzani, Pier Luigi; Concord Clinical School: MedicineBrentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial, The Lancet, vol.390, 10094, 2017,pp 555-566
2015Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaCarlino, Matteo; Long, Georgina; Chiarion-Sileni, Vanna; Cowey, C. Lance; Dummer, R; et al, Various; Gonzalez, Rene; Grob, Jean-Jacques; Lao, Christopher; Larkin, James; Schadendorf, Dirk; Smylie, Michael; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentreCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, The New England Journal of Medicine, vol.373, 1, 2015,pp 23-34
2015Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialLong, Georgina; Amonkar, Mayur M; Drucis, Kamil; Dummer, R; et al, Various; Grange, Florent; Grob, Jean Jacques; Karaszewska, Boguslawa; Mackiewicz, Andrzej; Schachter, Jacob; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreComparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial, The Lancet Oncology, vol.16, 13, 2015,pp 1389-1398
2015Improved overall survival in melanoma with combined dabrafenib and trametinibLong, Georgina; Chiarion-Sileni, Vanna; Dummer, R; et al, Various; Grange, Florent; Karaszewska, Boguslawa; Lichinitser, Michael; Mackiewicz, Andrzej; Mortier, Laurent; Robert, Caroline; Rutkowski, Piotr; Schachter, Jacob; Stroiakovski, Daniel; Central Clinical School: The Sydney Cancer CentreImproved overall survival in melanoma with combined dabrafenib and trametinib, New England Journal of Medicine, vol.372, 1, 2015,pp 30-39
2017Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical TrialsLong, Georgina; Atkinson, V; Dummer, R; et al, Various; Grob, Jean Jacques; Larkin, James; Márquez-Rodas, Ivan; McNeil, Catriona M.; Robert, Caroline; Schadendorf, Dirk; Schmidt, Henrik; Weber, Jeffrey; Northern Clinical School: MedicineNivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials, JAMA Oncology, vol.3, 11, 2017,pp 1511-1519
2017Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyLong, Georgina; Andtbacka, R; Cebon, Jonathan Simon; Dummer, R; et al, Various; Malvehy, Josep; Michielin, Olivier; Olszanski, Anthony; Puzanov, Igor; Ribas, Antoni; VanderWalde, Ari; Northern Clinical School: MedicineOncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy, Cell, vol.170, 6, 2017,pp 1109-1119
2014Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trialsKefford, Richard (Rick); Long, Georgina; Ascierto, Paolo; Dummer, R; Eggermont, Alexander; Flaherty, Keith; Hauschild, A; Hennig, Michael; Kirkwood, John; Lee, Sandra J; Lorigan, Paul; Mackensen, Andreas; McArthur, Grant A.; O'Day, Steven; Patel, Poulam; Robert, Caroline; Schadendorf, D; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreSurrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trials, The Lancet Oncology, vol.15, 3, 2014,pp 297-304
2015Treatment algorithms in stage IV melanomaKefford, Richard (Rick); Dummer, R; Eggermont, Alexander; Espinosa, E; Gogas, Helen; Grob, Jean-Jacques; Hauschild, Axel; Martin-Algarra, Salvador; Robert, C; Rutkowski, Piotr; Schadendorf, D; Western Clinical School: Westmead Institute for Medical ResTreatment algorithms in stage IV melanoma, American Journal of Therapeutics, vol.22, 1, 2015,pp 61-67